Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Predicting drug susceptibility of non–small cell lung cancers based on genetic lesions
Martin L. Sos, … , Kwok-Kin Wong, Roman K. Thomas
Martin L. Sos, … , Kwok-Kin Wong, Roman K. Thomas
Published May 18, 2009
Citation Information: J Clin Invest. 2009;119(6):1727-1740. https://doi.org/10.1172/JCI37127.
View: Text | PDF
Technical Advance Oncology Article has an altmetric score of 12

Predicting drug susceptibility of non–small cell lung cancers based on genetic lesions

  • Text
  • PDF
Abstract

Somatic genetic alterations in cancers have been linked with response to targeted therapeutics by creation of specific dependency on activated oncogenic signaling pathways. However, no tools currently exist to systematically connect such genetic lesions to therapeutic vulnerability. We have therefore developed a genomics approach to identify lesions associated with therapeutically relevant oncogene dependency. Using integrated genomic profiling, we have demonstrated that the genomes of a large panel of human non–small cell lung cancer (NSCLC) cell lines are highly representative of those of primary NSCLC tumors. Using cell-based compound screening coupled with diverse computational approaches to integrate orthogonal genomic and biochemical data sets, we identified molecular and genomic predictors of therapeutic response to clinically relevant compounds. Using this approach, we showed that v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations confer enhanced Hsp90 dependency and validated this finding in mice with KRAS-driven lung adenocarcinoma, as these mice exhibited dramatic tumor regression when treated with an Hsp90 inhibitor. In addition, we found that cells with copy number enhancement of v-abl Abelson murine leukemia viral oncogene homolog 2 (ABL2) and ephrin receptor kinase and v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian) (SRC) kinase family genes were exquisitely sensitive to treatment with the SRC/ABL inhibitor dasatinib, both in vitro and when it xenografted into mice. Thus, genomically annotated cell-line collections may help translate cancer genomics information into clinical practice by defining critical pathway dependencies amenable to therapeutic inhibition.

Authors

Martin L. Sos, Kathrin Michel, Thomas Zander, Jonathan Weiss, Peter Frommolt, Martin Peifer, Danan Li, Roland Ullrich, Mirjam Koker, Florian Fischer, Takeshi Shimamura, Daniel Rauh, Craig Mermel, Stefanie Fischer, Isabel Stückrath, Stefanie Heynck, Rameen Beroukhim, William Lin, Wendy Winckler, Kinjal Shah, Thomas LaFramboise, Whei F. Moriarty, Megan Hanna, Laura Tolosi, Jörg Rahnenführer, Roel Verhaak, Derek Chiang, Gad Getz, Martin Hellmich, Jürgen Wolf, Luc Girard, Michael Peyton, Barbara A. Weir, Tzu-Hsiu Chen, Heidi Greulich, Jordi Barretina, Geoffrey I. Shapiro, Levi A. Garraway, Adi F. Gazdar, John D. Minna, Matthew Meyerson, Kwok-Kin Wong, Roman K. Thomas

×

Total citations by year

Year: 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 Total
Citations: 1 1 3 3 3 7 6 10 10 11 11 15 16 16 15 6 1 135
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (135)

Title and authors Publication Year
Cellular Mass Response to Therapy Correlates With Clinical Response for a Range of Malignancies.
Stevens MM, Kimmerling RJ, Olcum S, Vacha M, LaBella R, Minnah A, Katsis K, Fujii J, Shaheen Z, Sundaresan S, Criscitiello J, Niesvizky R, Raje N, Branagan A, Krishnan A, Jagannath S, Parekh S, Sperling AS, Rosenbaum CA, Munshi N, Luskin MR, Tamrazi A, Reid CA
JCO Precision Oncology 2024
Progress in patient-derived liver cancer cell models: a step forward for precision medicine.
Zhang Z, Hui L
Acta Biochimica et Biophysica Sinica 2023
Patient-Derived In Vitro and In Vivo Models of Cancer.
Claridge SE, Cavallo JA, Hopkins BD
Advances in experimental medicine and biology 2022
The treatment of advanced non-small cell lung cancer harboring KRAS mutation: a new class of drugs for an old target—a narrative review
Spagnuolo A, Maione P, Gridelli C
Translational Lung Cancer Research 2022
May EPH/Ephrin Targeting Revolutionize Lung Cancer Treatment?
Psilopatis I, Karniadakis I, Danos KS, Vrettou K, Michaelidou K, Mavridis K, Agelaki S, Theocharis S
International journal of molecular sciences 2022
RUNX2 Phosphorylation by Tyrosine Kinase ABL Promotes Breast Cancer Invasion
F He, Y Matsumoto, Y Asano, Y Yamamura, T Katsuyama, JL Rose, N Tomonobu, NL Komalasari, M Sakaguchi, R Rottapel, J Wada
Frontiers in Oncology 2021
KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup
M Xie, X Xu, Y Fan
Frontiers in Oncology 2021
Role of the ABL tyrosine kinases in the epithelial–mesenchymal transition and the metastatic cascade
JH Luttman, A Colemon, B Mayro, AM Pendergast
Cell Communication and Signaling 2021
Measurement and models accounting for cell death capture hidden variation in compound response
SY Bae, N Guan, R Yan, K Warner, SD Taylor, AS Meyer
Cell Death and Disease 2020
Steroid receptor‐associated and regulated protein is a biomarker in predicting the clinical outcome and treatment response in malignancies
A Naderi
EMBO reports 2020
Emerging Kinase Therapeutic Targets in Pancreatic Ductal Adenocarcinoma and Pancreatic Cancer Desmoplasia
JF Creeden, K Alganem, AS Imami, ND Henkel, FC Brunicardi, SH Liu, R Shukla, T Tomar, F Naji, RE McCullumsmith
International journal of molecular sciences 2020
Predicting responses to platin chemotherapy agents with biochemically-inspired machine learning
EJ Mucaki, JZ Zhao, DJ Lizotte, PK Rogan
Signal Transduction and Targeted Therapy 2019
mTORC1 inhibitor RAD001 (everolimus) enhances non-small cell lung cancer cell radiosensitivity in vitro via suppressing epithelial–mesenchymal transition
Y Chen, W LI, P Peng, W Zhao, Y Tian, Y Huang, S Xia, Y Chen
Acta Pharmacologica Sinica 2019
Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance
BC Creelan, JE Gray, T Tanvetyanon, AA Chiappori, T Yoshida, MJ Schell, SJ Antonia, EB Haura
British Journal of Cancer 2019
An Interactive Resource to Probe Genetic Diversity and Estimated Ancestry in Cancer Cell Lines
J Dutil, Z Chen, AN Monteiro, JK Teer, SA Eschrich
Cancer research 2019
Xenograft and organoid model systems in cancer research
M Bleijs, M Wetering, H Clevers, J Drost
The EMBO Journal 2019
Probabilistic modeling of personalized drug combinations from integrated chemical screen and molecular data in sarcoma
NE Berlow, R Rikhi, M Geltzeiler, J Abraham, MN Svalina, LE Davis, E Wise, M Mancini, J Noujaim, A Mansoor, MJ Quist, KL Matlock, MW Goros, BS Hernandez, YC Doung, K Thway, T Tsukahara, J Nishio, ET Huang, S Airhart, CJ Bult, R Gandour-Edwards, RG Maki, RL Jones, JE Michalek, M Milovancev, S Ghosh, R Pal, C Keller
BMC Cancer 2019
A Pharmacogenomic Landscape in Human Liver Cancers
Z Qiu, H Li, Z Zhang, Z Zhu, S He, X Wang, P Wang, J Qin, L Zhuang, W Wang, F Xie, Y Gu, K Zou, C Li, C Li, C Wang, J Cen, X Chen, Y Shu, Z Zhang, L Sun, L Min, Y Fu, X Huang, H Lv, H Zhou, Y Ji, Z Zhang, Z Meng, X Shi, H Zhang, Y Li, L Hui
Cancer Cell 2019
A combined tissue-engineered/ in silico signature tool patient stratification in lung cancer
C Göttlich, M Kunz, C Zapp, SL Nietzer, H Walles, T Dandekar, G Dandekar
Molecular Oncology 2018
Mutations, protein homeostasis, and epigenetic control of genome integrity
JL Xie, DF Jarosz
DNA repair 2018
Targeting an oncogenic kinase/phosphatase signaling network for cancer therapy
XM Qi, F Wang, M Mortensen, R Wertz, G Chen
Acta pharmaceutica Sinica. B 2018
YAP and TAZ in Lung Cancer: Oncogenic Role and Clinical Targeting
FL Sardo, S Strano, G Blandino
Cancers 2018
A Phase Ib/II Study of Ganetespib With Doxorubicin in Advanced Solid Tumors Including Relapsed-Refractory Small Cell Lung Cancer
DS Subramaniam, SV Liu, J Crawford, J Kramer, J Thompson, H Wang, G Giaccone
Frontiers in Oncology 2018
Cell-Based Methods for Determination of Efficacy for Candidate Therapeutics in the Clinical Management of Cancer
J Gordon, M Brown, M Reynolds
Diseases 2018
Methods, Tools and Current Perspectives in Proteogenomics
KV Ruggles, K Krug, X Wang, KR Clauser, J Wang, SH Payne, D Fenyö, B Zhang, DR Mani
Molecular & cellular proteomics : MCP 2017
Mechanoresponsive stem cells to target cancer metastases through biophysical cues
L Liu, SX Zhang, W Liao, HP Farhoodi, CW Wong, CC Chen, AI Ségaliny, JV Chacko, LP Nguyen, M Lu, G Polovin, EJ Pone, TL Downing, DA Lawson, MA Digman, W Zhao
Science Translational Medicine 2017
Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma
J Brägelmann, MA Dammert, F Dietlein, JM Heuckmann, A Choidas, S Böhm, A Richters, D Basu, V Tischler, C Lorenz, P Habenberger, Z Fang, S Ortiz-Cuaran, F Leenders, J Eickhoff, U Koch, M Getlik, M Termathe, M Sallouh, Z Greff, Z Varga, H Balke-Want, CA French, M Peifer, HC Reinhardt, L Örfi, G Kéri, S Ansén, LC Heukamp, R Büttner, D Rauh, BM Klebl, RK Thomas, ML Sos
Cell Reports 2017
Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors
D Plenker, M Riedel, J Brägelmann, MA Dammert, R Chauhan, PP Knowles, C Lorenz, M Keul, M Bührmann, O Pagel, V Tischler, AH Scheel, D Schütte, Y Song, J Stark, F Mrugalla, Y Alber, A Richters, J Engel, F Leenders, JM Heuckmann, J Wolf, J Diebold, G Pall, M Peifer, M Aerts, K Gevaert, RP Zahedi, R Buettner, KM Shokat, NQ McDonald, SM Kast, O Gautschi, RK Thomas, ML Sos
Science Translational Medicine 2017
Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer
B Gaschler-Markefski, P Sikken, JV Heymach, M Gottfried, A Mellemgaard, S Novello, CN Gann, J Barrueco, M Reck, NH Hanna, R Kaiser
ESMO Open 2017
Ex vivo tumor culture systems for functional drug testing and therapy response prediction
TG Meijer, KA Naipal, A Jager, DC van Gent
Future Science OA 2017
Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer
CM Parseghian, NU Parikh, JY Wu, ZQ Jiang, L Henderson, F Tian, B Pastor, M Ychou, K Raghav, A Dasari, DR Fogelman, AD Katsiampoura, DG Menter, RA Wolff, C Eng, MJ Overman, AR Thierry, GE Gallick, S Kopetz
Clinical cancer research 2017
Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells
A Rouhi, C Miller, S Grasedieck, S Reinhart, B Stolze, H Döhner, F Kuchenbauer, L Bullinger, S Fröhling, C Scholl
Oncotarget 2017
Implications of KRAS mutations in acquired resistance to treatment in NSCLC
MD Re, E Rofi, G Restante, S Crucitta, E Arrigoni, S Fogli, MD Maio, I Petrini, R Danesi
Oncotarget 2017
Sequential feature selection and inference using multi-variate random forests
J Mayer, R Rahman, S Ghosh, R Pal, J Kelso
Bioinformatics 2017
Inactivation of ABL kinases Suppresses Non-Small-Cell Lung Cancer Metastasis
Jing Jin Gu, Clay Rouse, Xia Xu, Jun Wang, Mark Onaitis, Ann Marie Pendergast
JCI Insight 2016
Targeting the KRAS Pathway in Non-Small Cell Lung Cancer
P Tomasini, P Walia, C Labbe, K Jao, NB Leighl
The oncologist 2016
Human Organotypic Lung Tumor Models: Suitable For Preclinical 18F-FDG PET-Imaging
D Fecher, E Hofmann, A Buck, R Bundschuh, S Nietzer, G Dandekar, T Walles, H Walles, K Lückerath, M Steinke, N Cordes
PloS one 2016
High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines
C Yu, AM Mannan, GM Yvone, KN Ross, YL Zhang, MA Marton, BR Taylor, A Crenshaw, JZ Gould, P Tamayo, BA Weir, A Tsherniak, B Wong, LA Garraway, AF Shamji, MA Palmer, MA Foley, W Winckler, SL Schreiber, AL Kung, TR Golub
Nature Biotechnology 2016
Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response
ML Nickerson, N Witte, KM Im, S Turan, C Owens, K Misner, SX Tsang, Z Cai, S Wu, M Dean, JC Costello, D Theodorescu
Oncogene 2016
The clinical pathological characteristics and prognosis of FGFR1 gene amplification in non-small-cell lung cancer: a meta-analysis
FJ Xie, HY Lu, QQ Zheng, J Qin, Y Gao, YP Zhang, X Hu, WM Mao
OncoTargets and therapy 2016
LYN expression predicts the response to dasatinib in a subpopulation of lung adenocarcinoma patients
YJ Kim, S Hong, M Sung, MJ Park, K Jung, KW Noh, DY Oh, MS Lee, E Oh, YK Shin, YL Choi
Oncotarget 2016
KRAS driven expression signature has prognostic power superior to mutation status in non-small cell lung cancer: Kras driven expression signature in NSCLC
Á Nagy, LS Pongor, A Szabó, M Santarpia, B Győrffy
International Journal of Cancer 2016
Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate
MM Stevens, CL Maire, N Chou, MA Murakami, DS Knoff, Y Kikuchi, RJ Kimmerling, H Liu, S Haidar, NL Calistri, N Cermak, S Olcum, NA Cordero, A Idbaih, PY Wen, DM Weinstock, KL Ligon, SR Manalis
Nature Biotechnology 2016
The Flint Animal Cancer Center (FACC) Canine Tumour Cell Line Panel: a resource for veterinary drug discovery, comparative oncology and translational medicine: Cell line panel for veterinary oncology
JS Fowles, DD Dailey, DL Gustafson, DH Thamm, DL Duval
Veterinary and Comparative Oncology 2016
Integrating phenotypic small-molecule profiling and human genetics: the next phase in drug discovery
CM Johannessen, PA Clemons, BK Wagner
Trends in Genetics 2015
A novel PI3K inhibitor iMDK suppresses non-small cell lung Cancer cooperatively with A MEK inhibitor
N Ishida, T Fukazawa, Y Maeda, T Yamatsuji, M Takaoka, M Haisa, E Yokota, K Shigemitsu, I Morita, K Kato, K Matsumoto, T Shimo, T Okui, XH Bao, H Hao, SN Grant, N Takigawa, JA Whitsett, Y Naomoto
Experimental Cell Research 2015
Appropriateness of Using Patient-Derived Xenograft Models for Pharmacologic Evaluation of Novel Therapies for Esophageal/Gastro-Esophageal Junction Cancers
L Dodbiba, J Teichman, A Fleet, H Thai, MH Starmans, R Navab, Z Chen, H Girgis, L Eng, O Espin-Garcia, X Shen, B Bandarchi, J Schwock, MS Tsao, H El-Zimaity, SD Der, W Xu, RG Bristow, GE Darling, PC Boutros, LE Ailles, G Liu, WA Phillips
PloS one 2015
Cancer Cell Line Panels Empower Genomics-Based Discovery of Precision Cancer Medicine
HS Kim, YJ Sung, S Paik
Yonsei Medical Journal 2015
The Emerging Role of ABL Kinases in Solid Tumors
J Wang, AM Pendergast
Trends in Cancer 2015
Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma
MB Schabath, EA Welsh, WJ Fulp, L Chen, JK Teer, ZJ Thompson, BE Engel, M Xie, AE Berglund, BC Creelan, SJ Antonia, JE Gray, SA Eschrich, DT Chen, WD Cress, EB Haura, AA Beg
Oncogene 2015
Pharmacogenomic agreement between two cancer cell line data sets
N Stransky, M Ghandi, GV Kryukov, LA Garraway, J Lehár, M Liu, D Sonkin, A Kauffmann, K Venkatesan, EJ Edelman, M Riester, J Barretina, G Caponigro, R Schlegel, WR Sellers, F Stegmeier, M Morrissey, A Amzallag, I Pruteanu-Malinici, DA Haber, S Ramaswamy, CH Benes, MP Menden, F Iorio, MR Stratton, U McDermott, MJ Garnett, J Saez-Rodriguez
Nature 2015
A Copula Based Approach for Design of Multivariate Random Forests for Drug Sensitivity Prediction
S Haider, R Rahman, S Ghosh, R Pal, A Gursoy
PloS one 2015
Mining the Breast Cancer Proteome for Predictors of Drug Sensitivity
LC Li, TY Wong
Journal of proteomics & bioinformatics 2015
Combination of heat shock protein 90 and focal adhesion kinase inhibitors synergistically inhibits the growth of non-small cell lung cancer cells
PJ Webber, C Park, M Qui, SS Ramalingam, FR Khuri, H Fu, Y Du
Oncoscience 2015
Tumor-Derived Cell Lines as Molecular Models of Cancer Pharmacogenomics
A Goodspeed, LM Heiser, JW Gray, JC Costello
Molecular cancer research : MCR 2015
Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype
M Larrayoz, R Pio, MJ Pajares, I Zudaire, D Ajona, O Casanovas, LM Montuenga, J Agorreta
EMBO Molecular Medicine 2014
Oncogenic RIT1 mutations in lung adenocarcinoma
AH Berger, M Imielinski, F Duke, J Wala, N Kaplan, GX Shi, DA Andres, M Meyerson
Oncogene 2014
A Diverse Stochastic Search Algorithm for Combination Therapeutics
MU Caglar, R Pal
BioMed Research International 2014
Systems biology approaches to develop innovative strategies for lung cancer therapy
K Viktorsson, R Lewensohn, B Zhivotovsky
Cell Death and Disease 2014
An Ensemble Based Top Performing Approach for NCI-DREAM Drug Sensitivity Prediction Challenge
Q Wan, R Pal
PloS one 2014
Genetic modifiers of EGFR dependence in non-small cell lung cancer
T Sharifnia, V Rusu, F Piccioni, M Bagul, M Imielinski, AD Cherniack, CS Pedamallu, B Wong, FH Wilson, LA Garraway, D Altshuler, TR Golub, DE Root, A Subramanian, M Meyerson
Proceedings of the National Academy of Sciences 2014
Association Between the Cytogenetic Profile of Tumor Cells and Response to Preoperative Radiochemotherapy in Locally Advanced Rectal Cancer:
M González-González, J Garcia, JA Alcazar, ML Gutiérrez, LM Gónzalez, O Bengoechea, MM Abad, A Santos-Briz, O Blanco, M Martín, A Rodríguez, M Fuentes, L Muñoz-Bellvis, A Orfao, JM Sayagues
Medicine 2014
Prediction of individual response to anticancer therapy: historical and future perspectives
FT Unger, I Witte, KA David
Cellular and Molecular Life Sciences 2014
BreaKmer: detection of structural variation in targeted massively parallel sequencing data using kmers
RP Abo, M Ducar, EP Garcia, AR Thorner, V Rojas-Rudilla, L Lin, LM Sholl, WC Hahn, M Meyerson, NI Lindeman, PV Hummelen, LE MacConaill
Nucleic Acids Research 2014
Not just gRASping at flaws: Finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers
H Ebi, AC Faber, JA Engelman, S Yano
Cancer Science 2014
Inference of dynamic biological networks based on responses to drug perturbations
N Berlow, L Davis, C Keller, R Pal
EURASIP Journal on Bioinformatics and Systems Biology 2014
Cell-autonomous autocrine VEGF:VEGFR2 feed-forward loop triggers the angiogenic switch in lung cancer
Sampurna Chatterjee, Lukas Heukamp, Maike Siobal, Jakob Schoettle, Caroline Wieczorek, Martin Peifer, Davide Frasca, Mirjam Koker, Katharina Koenig, Lydia Meder, Daniel Rauh, Reinhard Büttner, Juergen Wolf, Rolf Brekken, Bernd Neumaier, Gerhard Christofori, Roman Thomas, Roland Ullrich
Journal of Clinical Investigation 2013
Establishment of a human 3D lung cancer model based on a biological tissue matrix combined with a Boolean in silico model
AT Stratmann, D Fecher, G Wangorsch, C Göttlich, T Walles, H Walles, T Dandekar, G Dandekar, SL Nietzer
Molecular Oncology 2013
Molecular dissection of AKT activation in lung cancer cell lines
Y Guo, J Du, DJ Kwiatkowski
Molecular cancer research : MCR 2013
Inhibition of Ephrin B3-mediated survival signaling contributes to increased cell death response of non-small cell lung carcinoma cells after combined treatment with ionizing radiation and PKC 412
S Ståhl, VO Kaminskyy, G Efazat, AH Vaculova, S Rodriguez-Nieto, A Moshfegh, R Lewensohn, K Viktorsson, B Zhivotovsky
Cell Death and Disease 2013
Metrics other than potency reveal systematic variation in responses to cancer drugs
M Fallahi-Sichani, S Honarnejad, LM Heiser, JW Gray, PK Sorger
Nature Chemical Biology 2013
Targeted therapies in development for non-small cell lung cancer
T Reungwetwattana, GK Dy
Journal of carcinogenesis 2013
Proof of the concept to use a malignant B cell line drug screen strategy for identification and weight of melphalan resistance genes in multiple myeloma
M Bøgsted, AE Bilgrau, CP Wardell, U Bertsch, A Schmitz, JS Bødker, MK Kjeldsen, H Goldschmidt, GJ Morgan, K Dybkaer, HE Johnsen
PloS one 2013
Genomic and transcriptional alterations in lung adenocarcinoma in relation to EGFR and KRAS mutation status
M Planck, K Edlund, J Botling, P Micke, S Isaksson, J Staaf
PloS one 2013
A new approach for prediction of tumor sensitivity to targeted drugs based on functional data
N Berlow, LE Davis, EL Cantor, B Séguin, C Keller, R Pal
BMC bioinformatics 2013
Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cells
AY Chang, M Wang
BMC Cancer 2013
Collections of simultaneously altered genes as biomarkers of cancer cell drug response
DL Masica, R Karchin
Cancer research 2013
Integrated cistromic and expression analysis of amplified NKX2-1 in lung adenocarcinoma identifies LMO3 as a functional transcriptional target
H Watanabe, JM Francis, MS Woo, B Etemad, W Lin, DF Fries, S Peng, EL Snyder, PR Tata, F Izzo, AC Schinzel, J Cho, PS Hammerman, RG Verhaak, WC Hahn, J Rajagopal, T Jacks, M Meyerson
Genes & development 2013
Role of ABL Family Kinases in Cancer: from Leukemia to Solid Tumors
EK Greuber, P Smith-Pearson, J Wang, AM Pendergast
Nature Reviews Cancer 2013
A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non–Small Cell Lung Cancer
MA Socinski, J Goldman, I El-Hariry, M Koczywas, V Vukovic, L Horn, E Paschold, R Salgia, H West, LV Sequist, P Bonomi, J Brahmer, LC Chen, A Sandler, CP Belani, T Webb, H Harper, M Huberman, S Ramalingam, KK Wong, F Teofilovici, W Guo, GI Shapiro
Clinical cancer research 2013
Characteristics of Lung Cancers Harboring NRAS Mutations
K Ohashi, LV Sequist, ME Arcila, CM Lovly, , CM Rudin, T Moran, DR Camidge, CL Vnencak-Jones, L Berry, Y Pan, H Sasaki, JA Engelman, EB Garon, SM Dubinett, WA Franklin, GJ Riely, ML Sos, MG Kris, D Dias-Santagata, M Ladanyi, PA Bunn, W Pao
Clinical cancer research 2013
Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33
N Azoitei, CM Hoffmann, JM Ellegast, CR Ball, K Obermayer, U Gossele, B Koch, K Faber, F Genze, M Schrader, HA Kestler, H Dohner, G Chiosis, H Glimm, S Frohling, C Scholl
Journal of Experimental Medicine 2012
Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in In Vitro and In Vivo Models of Non–Small Cell Lung Cancer
T Shimamura, SA Perera, KP Foley, J Sang, SJ Rodig, T Inoue, L Chen, D Li, J Carretero, YC Li, P Sinha, CD Carey, CL Borgman, JP Jimenez, M Meyerson, W Ying, J Barsoum, KK Wong, GI Shapiro
Clinical cancer research 2012
Effects of Cancer-Associated EPHA3 Mutations on Lung Cancer
G Zhuang, W Song, K Amato, Y Hwang, K Lee, M Boothby, F Ye, Y Guo, Y Shyr, L Lin, DP Carbone, DM Brantley-Sieders, J Chen
JNCI Journal of the National Cancer Institute 2012
Hsp90 inhibition differentially destabilises MAP kinase and TGF-beta signalling components in cancer cells revealed by kinase-targeted chemoproteomics
A Haupt, G Joberty, M Bantscheff, H Fröhlich, H Stehr, MR Schweiger, A Fischer, M Kerick, ST Boerno, A Dahl, M Lappe, H Lehrach, C Gonzalez, G Drewes, BM Lange
BMC Cancer 2012
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
J Barretina, G Caponigro, N Stransky, K Venkatesan, AA Margolin, S Kim, CJ Wilson, J Lehár, GV Kryukov, D Sonkin, A Reddy, M Liu, L Murray, MF Berger, JE Monahan, P Morais, J Meltzer, A Korejwa, J Jané-Valbuena, FA Mapa, J Thibault, E Bric-Furlong, P Raman, A Shipway, IH Engels, J Cheng, GK Yu, J Yu, P Aspesi, M Silva, K Jagtap, MD Jones, L Wang, C Hatton, E Palescandolo, S Gupta, S Mahan, C Sougnez, RC Onofrio, T Liefeld, L MacConaill, W Winckler, M Reich, N Li, JP Mesirov, SB Gabriel, G Getz, K Ardlie, V Chan, VE Myer, BL Weber, J Porter, M Warmuth, P Finan, JL Harris, M Meyerson, TR Golub, MP Morrissey, WR Sellers, R Schlegel, LA Garraway
Nature 2012
Kinase-Impaired BRAF Mutations in Lung Cancer Confer Sensitivity to Dasatinib
B Sen, S Peng, X Tang, HS Erickson, H Galindo, T Mazumdar, DJ Stewart, I Wistuba, FM Johnson
Science Translational Medicine 2012
Differential Pathogenesis of Lung Adenocarcinoma Subtypes Involving Sequence Mutations, Copy Number, Chromosomal Instability, and Methylation
MD Wilkerson, X Yin, V Walter, N Zhao, CR Cabanski, MC Hayward, CR Miller, MA Socinski, AM Parsons, LB Thorne, BE Haithcock, NK Veeramachaneni, WK Funkhouser, SH Randell, PS Bernard, CM Perou, DN Hayes
PloS one 2012
Unlocking Pandora's box: personalising cancer cell death in non-small cell lung cancer
DA Fennell, C Swanton
The EPMA Journal 2012
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
M Peifer, L Fernández-Cuesta, ML Sos, J George, D Seidel, LH Kasper, D Plenker, F Leenders, R Sun, T Zander, R Menon, M Koker, I Dahmen, C Müller, VD Cerbo, HU Schildhaus, J Altmüller, I Baessmann, C Becker, B Wilde, J Vandesompele, D Böhm, S Ansén, F Gabler, I Wilkening, S Heynck, JM Heuckmann, X Lu, SL Carter, K Cibulskis, S Banerji, G Getz, KS Park, D Rauh, C Grütter, M Fischer, L Pasqualucci, G Wright, Z Wainer, P Russell, I Petersen, Y Chen, E Stoelben, C Ludwig, P Schnabel, H Hoffmann, T Muley, M Brockmann, W Engel-Riedel, LA Muscarella, VM Fazio, H Groen, W Timens, H Sietsma, E Thunnissen, E Smit, DA Heideman, PJ Snijders, F Cappuzzo, C Ligorio, S Damiani, J Field, S Solberg, OT Brustugun, M Lund-Iversen, J Sänger, JH Clement, A Soltermann, H Moch, W Weder, B Solomon, JC Soria, P Validire, B Besse, E Brambilla, C Brambilla, S Lantuejoul, P Lorimier, PM Schneider, M Hallek, W Pao, M Meyerson, J Sage, J Shendure, R Schneider, R Büttner, J Wolf, P Nürnberg, S Perner, LC Heukamp, PK Brindle, S Haas, RK Thomas
Nature Genetics 2012
A framework for identification of actionable cancer genome dependencies in small cell lung cancer
ML Sos, F Dietlein, M Peifer, J Schottle, H Balke-Want, C Muller, M Koker, A Richters, S Heynck, F Malchers, JM Heuckmann, D Seidel, PA Eyers, RT Ullrich, AP Antonchick, VV Vintonyak, PM Schneider, T Ninomiya, H Waldmann, R Buttner, D Rauh, LC Heukamp, RK Thomas
Proceedings of the National Academy of Sciences 2012
Recapitulation of tumor heterogeneity and molecular signatures in a 3D brain cancer model with decreased sensitivity to histone deacetylase inhibition
SJ Smith, M Wilson, JH Ward, CV Rahman, AC Peet, DC Macarthur, FR Rose, RG Grundy, R Rahman
PloS one 2012
Analysis of gene expression data from non-small cell lung carcinoma cell lines reveals distinct sub-classes from those identified at the phenotype level
AR Dalby, I Emam, R Franke
PloS one 2012
Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion
P Saintigny, S Peng, L Zhang, B Sen, II Wistuba, SM Lippman, L Girard, JD Minna, JV Heymach, FM Johnson
Molecular cancer therapeutics 2012
Phosphosignature predicts dasatinib response in non-small cell lung cancer
M Klammer, M Kaminski, A Zedler, F Oppermann, S Blencke, S Marx, S Müller, A Tebbe, K Godl, C Schaab
Molecular & cellular proteomics : MCP 2012
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.
McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Montalto G, Cervello M, Nicoletti F, Fagone P, Malaponte G, Mazzarino MC, Candido S, Libra M, Bäsecke J, Mijatovic S, Maksimovic-Ivanic D, Milella M, Tafuri A, Cocco L, Evangelisti C, Chiarini F, Martelli AM
Oncotarget 2012
Drug discovery: Cell lines battle cancer.
Weinstein JN
Nature 2012
KRAS Mouse Models: Modeling Cancer Harboring KRAS Mutations
RC O'Hagan, J Heyer
Genes & cancer 2011
MicroRNA Gene Dosage Alterations and Drug Response in Lung Cancer
KS Enfield, GL Stewart, LA Pikor, CE Alvarez, S Lam, WL Lam, R Chari
Journal of Biomedicine and Biotechnology 2011
Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer
A Dutt, AH Ramos, PS Hammerman, C Mermel, J Cho, T Sharifnia, A Chande, KE Tanaka, N Stransky, H Greulich, NS Gray, M Meyerson
PloS one 2011
Benchmarking of mutation diagnostics in clinical lung cancer specimens
S Querings, J Altmüller, S Ansén, T Zander, D Seidel, F Gabler, M Peifer, E Markert, K Stemshorn, B Timmermann, B Saal, S Klose, K Ernestus, M Scheffler, W Engel-Riedel, E Stoelben, E Brambilla, J Wolf, P Nürnberg, RK Thomas
PloS one 2011
Ras, ROS and Proteotoxic Stress: A Delicate Balance
W Xu, J Trepel, L Neckers
Cancer Cell 2011
miR2Gene: pattern discovery of single gene, multiple genes, and pathways by enrichment analysis of their microRNA regulators
C Qiu, J Wang, Q Cui
BMC Systems Biology 2011
NIRF constitutes a nodal point in the cell cycle network and is a candidate tumor suppressor
T Mori, DD Ikeda, T Fukushima, S Takenoshita, H Kochi
Cell cycle (Georgetown, Tex.) 2011
Allele-specific copy number analysis of tumor samples with aneuploidy and tumor heterogeneity
M Rasmussen, M Sundström, HG Kultima, J Botling, P Micke, H Birgisson, B Glimelius, A Isaksson
Genome biology 2011
ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors
JM Heuckmann, M Hölzel, ML Sos, S Heynck, H Balke-Want, M Koker, M Peifer, J Weiss, CM Lovly, C Grütter, D Rauh, W Pao, RK Thomas
Clinical cancer research 2011
A Platform for Rapid Detection of Multiple Oncogenic Mutations With Relevance to Targeted Therapy in Non–Small-Cell Lung Cancer
Z Su, D Dias-Santagata, M Duke, K Hutchinson, YL Lin, DR Borger, CH Chung, PP Massion, CL Vnencak-Jones, AJ Iafrate, W Pao
The Journal of molecular diagnostics : JMD 2011
EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks
M Wang, F Morsbach, D Sander, L Gheorghiu, A Nanda, C Benes, M Kriegs, M Krause, E Dikomey, M Baumann, J Dahm-Daphi, J Settleman, H Willers
Cancer research 2011
Amplification of CRKL Induces Transformation and Epidermal Growth Factor Receptor Inhibitor Resistance in Human Non–Small Cell Lung Cancers
HW Cheung, J Du, JS Boehm, F He, BA Weir, X Wang, M Butaney, LV Sequist, B Luo, JA Engelman, DE Root, M Meyerson, TR Golub, PA Jänne, WC Hahn
Cancer Discovery 2011
Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer
PS Hammerman, ML Sos, AH Ramos, C Xu, A Dutt, W Zhou, LE Brace, BA Woods, W Lin, J Zhang, X Deng, SM Lim, S Heynck, M Peifer, JR Simard, MS Lawrence, RC Onofrio, HB Salvesen, D Seidel, T Zander, JM Heuckmann, A Soltermann, H Moch, M Koker, F Leenders, F Gabler, S Querings, S Ansén, E Brambilla, C Brambilla, P Lorimier, OT Brustugun, Å Helland, I Petersen, JH Clement, H Groen, W Timens, H Sietsma, E Stoelben, J Wolf, DG Beer, MS Tsao, M Hanna, C Hatton, MJ Eck, PA Janne, BE Johnson, W Winckler, H Greulich, AJ Bass, J Cho, D Rauh, NS Gray, KK Wong, EB Haura, RK Thomas, M Meyerson
Cancer Discovery 2011
Integration and analysis of genome-scale data from gliomas
Riddick G, Fine HA
Nature reviews. Neurology 2011
[Oncology and palliative medicine].
Gärtner J, Wolf J, Voltz R, Hallek M
Der Internist 2011
Advances in the preclinical testing of cancer therapeutic hypotheses.
Caponigro G, Sellers WR
Nature reviews. Drug discovery 2011
Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
J Weiss, ML Sos, D Seidel, M Peifer, T Zander, JM Heuckmann, RT Ullrich, R Menon, S Maier, A Soltermann, H Moch, P Wagener, F Fischer, S Heynck, M Koker, J Schottle, F Leenders, F Gabler, I Dabow, S Querings, LC Heukamp, H Balke-Want, S Ansen, D Rauh, I Baessmann, J Altmuller, Z Wainer, M Conron, G Wright, P Russell, B Solomon, E Brambilla, C Brambilla, P Lorimier, S Sollberg, OT Brustugun, W Engel-Riedel, C Ludwig, I Petersen, J Sanger, J Clement, H Groen, W Timens, H Sietsma, E Thunnissen, E Smit, D Heideman, F Cappuzzo, C Ligorio, S Damiani, M Hallek, R Beroukhim, W Pao, B Klebl, M Baumann, R Buettner, K Ernestus, E Stoelben, J Wolf, P Nurnberg, S Perner, RK Thomas
Science Translational Medicine 2010
Analysis of compound synergy in high-throughput cellular screens by population-based lifetime modeling
M Peifer, J Weiss, ML Sos, M Koker, S Heynck, C Netzer, S Fischer, H Rode, D Rauh, J Rahnenführer, RK Thomas
PloS one 2010
Oncologist’s/haematologist’s view on the roles of pathologists for molecular targeted cancer therapy
U Keller, NV Bubnoff, C Peschel, J Duyster
Journal of Cellular and Molecular Medicine 2010
Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents
SV Sharma, DA Haber, J Settleman
Nature Reviews Cancer 2010
Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors
J Voortman, JH Lee, JK Killian, M Suuriniemi, Y Wang, M Lucchi, WI Smith, P Meltzer, Y Wang, G Giaccone
Proceedings of the National Academy of Sciences 2010
Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer
EB Haura, T Tanvetyanon, A Chiappori, C Williams, G Simon, S Antonia, J Gray, S Litschauer, L Tetteh, A Neuger, L Song, B Rawal, MJ Schell, G Bepler
Journal of Clinical Oncology 2010
Phase II Study of Dasatinib in Patients With Advanced Non–Small-Cell Lung Cancer
FM Johnson, BN Bekele, L Feng, I Wistuba, XM Tang, HT Tran, JJ Erasmus, LL Hwang, N Takebe, GR Blumenschein, SM Lippman, DJ Stewart
Journal of Clinical Oncology 2010
Lung Cancer Cell Lines as Tools for Biomedical Discovery and Research
AF Gazdar, L Girard, WW Lockwood, WL Lam, JD Minna
JNCI Journal of the National Cancer Institute 2010
Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine
D Dias-Santagata, S Akhavanfard, SS David, K Vernovsky, G Kuhlmann, SL Boisvert, H Stubbs, U McDermott, J Settleman, EL Kwak, JW Clark, SJ Isakoff, LV Sequist, JA Engelman, TJ Lynch, DA Haber, DN Louis, LW Ellisen, DR Borger, AJ Iafrate
EMBO Molecular Medicine 2010
Multigene Expression–Based Predictors for Sensitivity to Vorinostat and Velcade in Non–Small Cell Lung Cancer
AS Nagji, SH Cho, Y Liu, JK Lee, DR Jones
Molecular cancer therapeutics 2010
Guidance molecules in lung cancer.
Nasarre P, Potiron V, Drabkin H, Roche J
Cell adhesion & migration 2010
Towards patient-based cancer therapeutics
Nature Biotechnology 2010
Amplicon-Dependent CCNE1 Expression Is Critical for Clonogenic Survival after Cisplatin Treatment and Is Correlated with 20q11 Gain in Ovarian Cancer
Etemadmoghadam D, George J, Cowin PA, Cullinane C, Kansara M, Gorringe KL, Smyth GK, Bowtell DD
PloS one 2010
History of leukemia-lymphoma cell lines.
Drexler HG, Macleod RA
Human Cell 2010
Kinase inhibitors: narrowing down the real targets.
Daub H
Nature Chemical Biology 2010
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2009
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer
ML Sos, S Fischer, R Ullrich, M Peifer, JM Heuckmann, M Koker, S Heynck, I Stückrath, J Weiss, F Fischer, K Michel, A Goel, L Regales, KA Politi, S Perera, M Getlik, LC Heukamp, S Ansén, T Zander, R Beroukhim, H Kashkar, KM Shokat, WR Sellers, D Rauh, C Orr, KP Hoeflich, L Friedman, KK Wong, W Pao, RK Thomas
Proceedings of the National Academy of Sciences 2009
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
DA Barbie, P Tamayo, JS Boehm, SY Kim, SE Moody, IF Dunn, AC Schinzel, P Sandy, E Meylan, C Scholl, S Fröhling, EM Chan, ML Sos, K Michel, C Mermel, SJ Silver, BA Weir, JH Reiling, Q Sheng, PB Gupta, RC Wadlow, H Le, S Hoersch, BS Wittner, S Ramaswamy, DM Livingston, DM Sabatini, M Meyerson, RK Thomas, ES Lander, JP Mesirov, DE Root, DG Gilliland, T Jacks, WC Hahn
Nature 2009
High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507)
Y Gong, E Yao, R Shen, A Goel, M Arcila, J Teruya-Feldstein, MF Zakowski, S Frankel, M Peifer, RK Thomas, M Ladanyi, W Pao
PloS one 2009
Integrating complex genomic datasets and tumour cell sensitivity profiles to address a 'simple' question: which patients should get this drug?
C Benes, J Settleman
BMC Medicine 2009
Amplification of chromosomal segment 4q12 in non-small cell lung cancer
Ramos AH, Dutt A, Mermel C, Perner S, Cho J, Lafargue CJ, Johnson LA, Stiedl AC, Tanaka KE, Bass AJ, Barretina J, Weir BA, Beroukhim R, Thomas RK, Minna JD, Chirieac LR, Lindeman NI, Giordano T, Beer DG, Wagner P, Wistuba II, Rubin MA, Meyerson M
Cancer biology & therapy 2009
Standardized high-throughput evaluation of cell-based compound screens
P Frommolt, RK Thomas
BMC bioinformatics 2008

← Previous 1 2 3 4 5 6 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 15 patents
225 readers on Mendeley
1 readers on CiteULike
See more details